• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

培高利特剂量依从性及影响马属动物脑垂体中间叶机能减退症实验室控制的因素。

Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.

机构信息

Department of Clinical Sciences and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, UK.

Liphook Equine Hospital, Liphook, Hampshire, UK.

出版信息

Vet Rec. 2021 Jul;189(1):e142. doi: 10.1002/vetr.142. Epub 2021 Mar 23.

DOI:10.1002/vetr.142
PMID:33759215
Abstract

BACKGROUND

Equine pituitary pars intermedia dysfunction (PPID) is treated with daily pergolide therapy. Owner compliance and its effect on PPID control have not been previously investigated.

METHODS

Clinical records were searched to identify the sample of animals with PPID treated with pergolide from 2016 to 2019. The signalment was noted and the dose of pergolide received calculated. Animals were classified as compliant (receiving ≥90% of the veterinarian recommended dose of pergolide) or non-compliant, and as controlled (follow-up basal adrenocorticotrophic hormone concentrations within the reference range) or not.

RESULTS

In total, 110 animals were included. The majority (85%) were ≥16 years (mean ± SD 19.8 ± 4.4 years); the most common breeds were Cob (18%), Thoroughbred (16%) and Welsh (15%); 37% were female and 63% male. Overall, 48% were compliant and 52% non-compliant. There was no significant effect of compliance on laboratory control. Of those that were compliant, 74% were controlled, while 67% of non-compliant animals were controlled. Univariable analysis revealed a significant (p < 0.001) effect of age and breed on compliance and control, and of sex on control. On multivariable analysis, only age (compliance) and breed (compliance and control) were retained in the final model.

CONCLUSION

Only half of animals received the recommended pergolide dose; however, this did not affect laboratory control of PPID.

摘要

背景

马属动物脑垂体中间叶功能减退症(PPID)采用每日培高利特治疗。此前尚未对主人的依从性及其对 PPID 控制的影响进行研究。

方法

检索临床记录,以确定 2016 年至 2019 年期间接受培高利特治疗的患有 PPID 的动物样本。记录了动物的特征,并计算了培高利特的剂量。将动物分为依从性(接受兽医推荐剂量的培高利特≥90%)或不依从性,以及控制性(随访基础促肾上腺皮质激素浓度在参考范围内)或非控制性。

结果

共纳入 110 例动物。大多数(85%)年龄≥16 岁(平均±标准差 19.8±4.4 岁);最常见的品种为考比马(18%)、纯血马(16%)和威尔士马(15%);37%为雌性,63%为雄性。总体而言,48%的动物为依从性,52%的动物为不依从性。依从性对实验室控制无显著影响。在依从性的动物中,74%的动物得到控制,而非依从性动物中,67%的动物得到控制。单变量分析显示,年龄和品种对依从性和控制有显著影响(p<0.001),而性别对控制有显著影响。多变量分析显示,仅年龄(依从性)和品种(依从性和控制)保留在最终模型中。

结论

只有一半的动物接受了推荐的培高利特剂量;然而,这并未影响 PPID 的实验室控制。

相似文献

1
Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.培高利特剂量依从性及影响马属动物脑垂体中间叶机能减退症实验室控制的因素。
Vet Rec. 2021 Jul;189(1):e142. doi: 10.1002/vetr.142. Epub 2021 Mar 23.
2
BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.BEVA初级保健临床指南:马垂体中间叶功能障碍的诊断与管理
Equine Vet J. 2024 Mar;56(2):220-242. doi: 10.1111/evj.14009. Epub 2023 Oct 5.
3
Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.脑垂体中叶机能减退症和 Prascend(培高利特片剂)对马的内分泌和免疫功能的影响。
Domest Anim Endocrinol. 2021 Jan;74:106531. doi: 10.1016/j.domaniend.2020.106531. Epub 2020 Jul 29.
4
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.使用培高利特恢复中间部垂体多巴胺浓度和酪氨酸羟化酶表达水平:来自患有垂体中间部功能减退症的马的证据。
BMC Vet Res. 2020 Sep 25;16(1):356. doi: 10.1186/s12917-020-02565-3.
5
Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.甲磺酸培高利特在患有垂体中叶功能减退的马中经口给药后的药代动力学和药效学。
Domest Anim Endocrinol. 2019 Jul;68:135-141. doi: 10.1016/j.domaniend.2019.01.008. Epub 2019 Feb 8.
6
Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.培高利特治疗马属动物脑垂体中叶机能减退症的疗效:系统评价。
Vet J. 2020 Dec;266:105562. doi: 10.1016/j.tvjl.2020.105562. Epub 2020 Oct 8.
7
Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.长期给患有垂体中间部功能障碍的马匹施用甲磺酸培高利特后的药代动力学和药效学特性。
J Vet Pharmacol Ther. 2017 Apr;40(2):158-164. doi: 10.1111/jvp.12339. Epub 2016 Jun 15.
8
Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.疑似临床前垂体中间叶功能障碍的马匹在培高利特治疗前后的粪便圆线虫卵计数。
Vet J. 2018 May;235:60-62. doi: 10.1016/j.tvjl.2018.03.007. Epub 2018 Mar 23.
9
Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.垂体中叶功能减退的马应用培高利特对左心室功能影响的初步研究。
J Vet Sci. 2021 Sep;22(5):e64. doi: 10.4142/jvs.2021.22.e64.
10
Equine pituitary pars intermedia dysfunction.马垂体中间部功能障碍
Vet Clin North Am Equine Pract. 2011 Apr;27(1):93-113. doi: 10.1016/j.cveq.2010.12.007.

引用本文的文献

1
Long-Term Response of Equids With Pituitary Pars Intermedia Dysfunction to Treatment With Pergolide.患有垂体中间部功能障碍的马属动物对培高利特治疗的长期反应。
J Vet Intern Med. 2025 May-Jun;39(3):e70109. doi: 10.1111/jvim.70109.
2
Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction.对长效卡麦角林在马垂体中间部功能障碍管理中的应用进行回顾性评估。
Front Vet Sci. 2024 Mar 6;11:1332337. doi: 10.3389/fvets.2024.1332337. eCollection 2024.